Vaxart, Inc. (VXRT) analyst actions
Rating and price-target actions on VXRT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VXRT overview →
3 measured VXRT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | Press release | -0.21% | -1.94% | |
| Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate | Press release | +0.00% | +0.65% | |
| Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | Press release | +0.59% | -3.18% |
Keep exploring
More VXRT: earnings → · SEC filings → · VXRT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. - Class A (IRWD) | 342 | +0.07% | 50% |
| Brookdale Senior Living Inc. (BKD) | 341 | +0.36% | 62% |
| Cidara Therapeutics, Inc. (CDTX) | 339 | +0.06% | 52% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.